• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc. (Amendment)

    9/11/23 11:15:40 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $EYPT alert in real time by email
    SC 13G/A 1 eyep23a4.htm eyep23a4.htm - Generated by SEC Publisher for SEC Filing  

     

              CUSIP NO. 30233G209                       13G                             Page 1 of 14

     

     

                                                                                       UNITED STATES

                                                                  SECURITIES AND EXCHANGE COMMISSION

                                                                              Washington, D.C. 20549

     

                                                                                        SCHEDULE 13G

     

                                                           Under the Securities Exchange Act of 1934

                                                                                  (Amendment No. 4)*

     

                                                                      EyePoint Pharmaceuticals, Inc.

                                                                                    (Name of Issuer)

     

                                                                      Common Stock, par value $0.001

                                                                      (Title of Class of Securities)

     

                                                                                           30233G209

                                                                                      (CUSIP Number)

     

                                                                                     August 31, 2023

                                             (Date of Event Which Requires Filing of this Statement)

     

                 Check the appropriate box to designate the rule pursuant to which this Schedule is

                 filed:

                 [X] Rule 13d‑1(b)

                 [ ] Rule 13d‑1(c)

                 [ ] Rule 13d‑1(d)

     

                 *The remainder of this cover page shall be filled out for a reporting person's

                 initial filing on this form with respect to the subject class of securities, and

                 for any subsequent amendment containing information which would alter the

                 disclosures provided in a prior cover page.

     

                 The information required in the remainder of this cover page shall not be deemed to

                 be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934

                 ("Act") or otherwise subject to the liabilities of that section of the Act but

                 shall be subject to all other provisions of the Act (however, see the Notes).

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 2 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.

     

                          Franklin Resources, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          Delaware

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.     SOLE VOTING POWER

     

                                        (See Item 4)

     

                          6.     SHARED VOTING POWER

     

                                        (See Item 4)

     

                          7.     SOLE DISPOSITIVE POWER

     

                                        (See Item 4)

     

                          8.     SHARED DISPOSITIVE POWER

     

                                        (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                         4,130,137

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          11.8%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, CO (See Item 4)

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 3 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Charles B. Johnson

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                     (See Item 4)

     

                          6.    SHARED VOTING POWER

     

                                     (See Item 4)

     

                          7.    SOLE DISPOSITIVE POWER

     

                                     (See Item 4)

     

                          8.    SHARED DISPOSITIVE POWER

     

                                     (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                        (See Item 4)

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                         CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                        (See Item 4)

     

              12.   TYPE OF REPORTING PERSON

     

                         HC, IN (See Item 4)

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 4 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Rupert H. Johnson, Jr.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                      (See Item 4)

     

                          6.    SHARED VOTING POWER

     

                                      (See Item 4)

     

                          7.    SOLE DISPOSITIVE POWER

     

                                      (See Item 4)

     

                          8.    SHARED DISPOSITIVE POWER

     

                                      (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                         (See Item 4)

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          (See Item 4)

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 5 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Franklin Advisers, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          California

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                      4,089,622

     

                          6.    SHARED VOTING POWER

     

                                     0

     

                          7.    SOLE DISPOSITIVE POWER

     

                                      4,089,622

     

                          8.    SHARED DISPOSITIVE POWER

     

                                     0

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                         4,089,622

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          11.7%

     

              12.   TYPE OF REPORTING PERSON

     

                          IA, CO (See Item 4)

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 6 of 14

     

     

              Item 1.

     

              (a)   Name of Issuer

     

                          EyePoint Pharmaceuticals, Inc.

     

              (b)   Address of Issuer's Principal Executive Offices

     

               480 Pleasant Street

               Watertown, MA 02472

     

              Item 2.

     

              (a)   Name of Person Filing

     

                          (i):   Franklin Resources, Inc.

     

                          (ii):  Charles B. Johnson

     

                          (iii): Rupert H. Johnson, Jr.

     

                          (iv):  Franklin Advisers, Inc.

     

     

              (b)   Address of Principal Business Office or, if none, Residence

     

                          (i), (ii), and (iii):

                          One Franklin Parkway

                          San Mateo, CA 94403‑1906

     

                          (iv):  One Franklin Parkway

                                        San Mateo, CA  94403‑1906

     

              (c)   Citizenship

     

                          (i):     Delaware

     

                          (ii) and (iii): USA

                          (iv): California

     

              (d)   Title of Class of Securities

     

                          Common Stock, par value $0.001

     

              (e)   CUSIP Number

     

                          30233G209

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 7 of 14

     

     

              Item 3. If this statement is filed pursuant to §§240.13d‑1(b) or 240.13d‑2(b) or (c),

                              check whether the person filing is a:

                            (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

                            (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

                            (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.

                                            78c).

     

                            (d) [ ] Investment company registered under section 8 of the Investment Company

                                            Act of 1940 (15 U.S.C 80a‑8).

     

                            (e) [X] An investment adviser in accordance with §240.13d‑1(b)(1)(ii)(E);

     

                            (f) [ ] An employee benefit plan or endowment fund in accordance with

                                            §240.13d‑1(b)(1)(ii)(F);

     

                            (g) [X] A parent holding company or control person in accordance with

                                            §240.13d‑1(b)(1)(ii)(G);

     

                            (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit

                                            Insurance Act (12 U.S.C. 1813);

     

                            (i) [ ] A church plan that is excluded from the definition of an investment

                                            company under section 3(c)(14) of the Investment Company Act of 1940 (15

                                            U.S.C. 80a‑3);

     

                            (j) [ ] A non‑U.S. institution in accordance with §240.13d‑1(b)(ii)(J);

     

                            (k) [ ] Group, in accordance with §240.13d 1(b)(1)(ii)(K).

     

                            If filing as a non‑U.S. institution in accordance with §240.13d‑1(b)(1)(ii) (J).

                            please specify the type of institution:

     

         Item 4. Ownership

     

                The securities reported herein are beneficially owned by one or more open or closed end

                investment companies or other managed accounts that are investment management clients of

                investment managers that are direct and indirect subsidiaries (each, an “Investment

                Management Subsidiary” and, collectively, the “Investment Management Subsidiaries”) of

                Franklin Resources Inc. (“FRI”), including the Investment Management Subsidiaries listed

                in this Item 4.  When an investment management contract (including a sub advisory

                agreement) delegates to an Investment Management Subsidiary investment discretion or

                voting power over the securities held in the investment advisory accounts that are

                subject to that agreement, FRI treats the Investment Management Subsidiary as having sole

                investment discretion or voting authority, as the case may be, unless the agreement

                specifies otherwise. Accordingly, each Investment Management Subsidiary reports on

                Schedule 13G that it has sole investment discretion and voting authority over the

                securities covered by any such investment management agreement, unless otherwise noted in

                this Item 4.  As a result, for purposes of Rule 13d‑3 under the Act, the Investment

                Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners

                of the securities reported in this Schedule 13G.

     

                Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is

                being reported in conformity with the guidelines articulated by the SEC staff in Release

                No. 34‑39538 (January 12, 1998) (the “1998 Release”) relating to organizations, such as

                FRI, where related entities exercise voting and investment powers over the securities

                being reported independently from each other. The voting and investment powers held by

                each of FRI’s affiliates whose ownership of securities is disaggregated from that of FRI

                in accordance with the 1998 Release (“FRI Disaggregated Affiliates”) are exercised

                independently from FRI and from all other Investment Management Subsidiaries (FRI, its

     

     

     

     

     

     


     
     

     

    CUSIP NO. 30233G209                          13G                                 Page 8 of 15

     

          affiliates and the Investment Management Subsidiaries other than FRI Disaggregated

               Affiliates are collectively, “FRI Aggregated Affiliates”). Furthermore, internal policies

               and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand,

               FRI establish informational barriers that prevent the flow among, on the one hand, FRI

               Disaggregated Affiliates (including preventing the flow between such entities), and, on

               the other hand, the FRI Aggregated Affiliates of information that relates to the voting

               and investment powers over the securities owned by their respective investment management

               clients. Consequently, FRI Disaggregated Affiliates report the securities over which they

               hold investment and voting power separately from the FRI Aggregated Affiliates for

               purposes of Section 13 of the Act.

     

               Charles B. Johnson and Rupert H. Johnson, Jr. (the “Principal Shareholders”) each own in

               excess of 10% of the outstanding common stock of FRI and are the principal stockholders

               of FRI.  FRI and the Principal Shareholders may be deemed to be, for purposes of Rule

               13d‑3 under the Act, the beneficial owners of securities held by persons and entities for

               whom or for which FRI subsidiaries provide investment management services.  The number of

               shares that may be deemed to be beneficially owned and the percentage of the class of

               which such shares are a part are reported in Items 9 and 11 of the cover pages for FRI

               and each of the Principal Shareholders. FRI, the Principal Shareholders and each of the

               Investment Management Subsidiaries disclaim any pecuniary interest in any of such

               securities. In addition, the filing of this Schedule 13G on behalf of the Principal

               Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be

               construed as an admission that any of them is, and each of them disclaims that it is, the

               beneficial owner, as defined in Rule 13d‑3, of any of the securities reported in this

               Schedule 13G.

     

               FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries

               believe that they are not a “group” within the meaning of Rule 13d‑5 under the Act and

               that they are not otherwise required to attribute to each other the beneficial ownership

               of the securities held by any of them or by any persons or entities for whom or for which

               the Investment Management Subsidiaries provide investment management services.

     

                        (a)     Amount beneficially owned:

     

                                       4,130,137

     

                        (b)     Percent of class:

     

                                        11.8%

     

                        (c)     Number of shares as to which the person has:

     

                                    (i)  Sole power to vote or to direct the vote

     

                                              Franklin Resources, Inc.:                                         0

     

                                              Charles B. Johnson:                                               0

     

                                              Rupert H. Johnson, Jr.:                                           0

     

                                              Franklin Advisers, Inc.:                                  4,089,622

     

                         Fiduciary Trust Company International:                       39,224

     

                         Fiduciary Trust International LLC:                            1,291

     

                                         

                                  (ii) Shared power to vote or to direct the vote                                         0

     

                                (iii)  Sole power to dispose or to direct the disposition of

     

                                              Franklin Resources, Inc.:                                         0

     

                                              Charles B. Johnson:                                               0

     

                         Rupert H. Johnson, Jr.:                                           0

     

                                              Franklin Advisers, Inc.:                                  4,089,622

     

                         Fiduciary Trust Company International:                       39,224

     

                         Fiduciary Trust International LLC:                            1,291

     

     


     
     
     

     

              CUSIP NO. 30233G209                       13G                             Page 9 of 14

     

     

              Item 5.  Ownership of Five Percent or Less of a Class

     

                               If this statement is being filed to report the fact that as of the date hereof

                               the reporting person has ceased to be the beneficial owner of more than five

                               percent of the class of securities, check the following [ ]. 

     

              Item 6.  Ownership of More than Five Percent on Behalf of Another Person

     

                               The clients of the Investment Management Subsidiaries, including investment

                               companies registered under the Investment Company Act of 1940 and other managed

                               accounts, have the right to receive or power to direct the receipt of dividends

                               from, and the proceeds from the sale of, the securities reported herein. 

     

              Item 7. Identification and Classification of the Subsidiary Which Acquired the Security

                               Being Reported on By the Parent Holding Company

     

                               See Attached Exhibit C

     

              Item 8. Identification and Classification of Members of the Group

     

                               Not Applicable

     

              Item 9. Notice of Dissolution of Group

     

                               Not Applicable

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 10 of 14

     

              Item 10.  Certification

     

              By signing below I certify that, to the best of my knowledge and belief, the securities

              referred to above were acquired and are held in the ordinary course of business and were

              not acquired and are not held for the purpose of or with the effect of changing or

              influencing the control of the issuer of the securities and were not acquired and are not

              held in connection with or as a participant in any transaction having that purpose or

                effect, other than activities solely in connection with a nomination under §240.14a‑11.

     

     

              This report shall not be construed as an admission by the persons filing the report that

              they are the beneficial owner of any securities covered by this report.

     

              Exhibits.

                                Exhibit A Joint Filing Agreement

                                Exhibit B Limited Powers of Attorney for Section 13 Reporting Obligations

                                Exhibit C Item 7 Identification and Classification of Subsidiaries

     

                                                                                        SIGNATURE

     

              After reasonable inquiry and to the best of my knowledge and belief, I certify that the

              information set forth in this statement is true, complete and correct.

     

              Dated:  September 8, 2023

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

         Franklin Advisers, Inc.

        

     

             

     

              By:     /s/VIRGINIA E. ROSAS

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Virginia E. Rosas

                             Assistant Secretary of Franklin Resources, Inc.

     

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                Secretary of Franklin Advisers, Inc.

     

               

     

        

                            

                            

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 11 of 14

     

     

              EXHIBIT A

     

              JOINT FILING AGREEMENT

     

              By signing below I certify that, to the best of my knowledge and belief, the securities

              referred to above were acquired and are held in the ordinary course of business and were

              not acquired and are not held for the purpose of or with the effect of changing or

              influencing the control of the issuer of the securities and were not acquired and are not

              held in connection with or as a participant in any transaction having that purpose or

              effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

              IN WITNESS WHEREOF, the undersigned have executed this agreement on September 8, 2023.

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

         Franklin Advisers, Inc.

        

     

             

     

              By:    /s/VIRGINIA E. ROSAS

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Virginia E. Rosas

                             Assistant Secretary of Franklin Resources, Inc.

     

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                Secretary of Franklin Advisers, Inc.

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 12 of 14

     

              EXHIBIT B

     

                                                                           LIMITED POWER OF ATTORNEY

                                                                                                 FOR

                                                             SECTION 13 AND 16 REPORTING OBLIGATIONS

     

      Know all by these presents, that the undersigned hereby makes, constitutes and appoints each

      of Alison E. Baur, Steven J. Gray, Beth McAuley O’Malley, Thomas C. Merchant, Kimberly H.

      Novotny, Virginia E. Rosas, Navid J. Tofigh and Lori A. Weber each acting individually, as the

      undersigned’s true and lawful attorney‑in‑fact, with full power and authority as hereinafter

      described on behalf of and in the name, place and stead of the undersigned to:

                1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and

      Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the

      United States Securities and Exchange Commission and any national securities exchanges

      relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed‑end company to which

      an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered

      necessary or advisable under Regulation S‑T and Sections 13(d) and 16(a) of the Securities

      Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from

      time to time (the “Exchange Act”); and

                2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf,

      information on transactions in the securities of any Reporting Entity from any person,

      including brokers, employee benefit plan administrators and trustees, and the undersigned

      hereby authorizes any such person to release any such information to the undersigned and

      approves and ratifies any such release of information; and

                3. perform any and all other acts which in the discretion of such attorney‑in‑fact are

      necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

                The undersigned acknowledges that:

                1. this Limited Power of Attorney authorizes, but does not require, each such

      attorney‑in‑fact to act in their discretion on information provided to such attorney‑in‑fact

      without independent verification of such information;

                2. any documents prepared and/or executed by any such attorney‑in‑fact on behalf of the

      undersigned pursuant to this Limited Power of Attorney will be in such form and will contain

      such information and disclosure as such attorney‑in‑fact, in his or her discretion, deems

      necessary or desirable;

                3. none of FRI, any Reporting Entity nor any of such attorneys‑in‑fact assumes (i) any

      liability for the undersigned’s responsibility to comply with the requirements of the Exchange

      Act, (ii) any liability of the undersigned for any failure to comply with such requirements,

      or (iii) any obligation or liability of the undersigned for profit disgorgement under Section

      16(b) of the Exchange Act; and

                4. this Limited Power of Attorney does not relieve the undersigned from responsibility

      for compliance with the undersigned’s obligations under the Exchange Act, including without

      limitation, the reporting requirements under Section 16 of the Exchange Act.

                The undersigned hereby gives and grants each of the foregoing attorneys‑in‑fact full

      power and authority to do and perform all and every act and thing whatsoever requisite,

      necessary or appropriate to be done in and about the foregoing matters as fully to all intents

      and purposes as the undersigned might or could do if present, hereby ratifying all that each

      such attorney‑in‑fact of, for and on behalf of the undersigned, shall lawfully do or cause to

      be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing

      attorneys‑in‑fact against any loss of any nature whatsoever arising in connection therewith.

                This Limited Power of Attorney shall remain in full force and effect until revoked by the

      undersigned in a signed writing delivered to each such attorney‑in‑fact.

                IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be

      executed as of this 16th day of August, 2021.

     

                                                                                                                                /s/Charles B. Johnson

                                                                                                                                Signature

     

                                                                                                                                Charles B. Johnson

                                                                                                                                Print Name

     

     


     
     

     

              CUSIP NO. 30233G209                       13G                             Page 13 of 14

     

     

                                                                           LIMITED POWER OF ATTORNEY

                                                                                                 FOR

                                                             SECTION 13 AND 16 REPORTING OBLIGATIONS

     

    Know all by these presents, that the undersigned hereby makes, constitutes and appoints each

      of Alison E. Baur, Steven J. Gray, Beth McAuley O’Malley, Thomas C. Merchant, Kimberly H.

      Novotny, Virginia E. Rosas, Navid J. Tofigh and Lori A. Weber each acting individually, as the

      undersigned’s true and lawful attorney‑in‑fact, with full power and authority as hereinafter

      described on behalf of and in the name, place and stead of the undersigned to:

                1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and

      Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the

      United States Securities and Exchange Commission and any national securities exchanges

      relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed‑end company to which

      an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered

      necessary or advisable under Regulation S‑T and Sections 13(d) and 16(a) of the Securities

      Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from

      time to time (the “Exchange Act”); and

                2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf,

      information on transactions in the securities of any Reporting Entity from any person,

      including brokers, employee benefit plan administrators and trustees, and the undersigned

      hereby authorizes any such person to release any such information to the undersigned and

      approves and ratifies any such release of information; and

                3. perform any and all other acts which in the discretion of such attorney‑in‑fact are

      necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

                The undersigned acknowledges that:

                1. this Limited Power of Attorney authorizes, but does not require, each such

      attorney‑in‑fact to act in their discretion on information provided to such attorney‑in‑fact

      without independent verification of such information;

                2. any documents prepared and/or executed by any such attorney‑in‑fact on behalf of the

      undersigned pursuant to this Limited Power of Attorney will be in such form and will contain

      such information and disclosure as such attorney‑in‑fact, in his or her discretion, deems

      necessary or desirable;

                3. none of FRI, any Reporting Entity nor any of such attorneys‑in‑fact assumes (i) any

      liability for the undersigned’s responsibility to comply with the requirements of the Exchange

      Act, (ii) any liability of the undersigned for any failure to comply with such requirements,

      or (iii) any obligation or liability of the undersigned for profit disgorgement under Section

      16(b) of the Exchange Act; and

                4. this Limited Power of Attorney does not relieve the undersigned from responsibility

      for compliance with the undersigned’s obligations under the Exchange Act, including without

      limitation, the reporting requirements under Section 16 of the Exchange Act.

                The undersigned hereby gives and grants each of the foregoing attorneys‑in‑fact full

      power and authority to do and perform all and every act and thing whatsoever requisite,

      necessary or appropriate to be done in and about the foregoing matters as fully to all intents

      and purposes as the undersigned might or could do if present, hereby ratifying all that each

      such attorney‑in‑fact of, for and on behalf of the undersigned, shall lawfully do or cause to

      be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing

      attorneys‑in‑fact against any loss of any nature whatsoever arising in connection therewith.

                This Limited Power of Attorney shall remain in full force and effect until revoked by the

      undersigned in a signed writing delivered to each such attorney‑in‑fact.

                IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be

      executed as of this 16th day of August, 2021.

     

                                                                                                                          /s/Rupert H. Johnson, Jr.

                                                                                                                          Signature

     

                                                                                                                          Rupert H. Johnson, Jr.

                                                                                                                          Print Name

     

     


     
     

     

    CUSIP NO.      30233G209                       13G                             Page 14 of 14

     

              EXHIBIT C

     

           Franklin Advisers, Inc.                                     Item 3 Classification: 3(e)

     

           Fiduciary Trust International LLC                                                     Item 3 Classification: 3(e)

     

           Fiduciary Trust Company International                                             Item 3 Classification: 3(b)

     

     

     

     

    Get the next $EYPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYPT

    DatePrice TargetRatingAnalyst
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    1/7/2025$33.00Buy
    Citigroup
    10/16/2024Sector Outperform
    Scotiabank
    8/28/2024$15.00Buy
    Jefferies
    1/22/2024$35.00Overweight
    JP Morgan
    11/2/2023$20.00Buy
    Mizuho
    4/21/2023$33.00Outperform
    Robert W. Baird
    7/7/2022$21.00Buy
    Chardan Capital Markets
    More analyst ratings

    $EYPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that George O. Elston, Executive Vice President and Chief Financial Officer of EyePoint, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 am ET. A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepoint.bio. About EyePoint EyePoint, Inc. (NASDAQ:EYPT) is a clinical-stage biopharmaceutic

    2/5/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 13,900 shares of EyePoint common stock to three new employees. The stock options were granted on January 15, 2026. The grants were approved by the Compensation Committee and made as an inducement mater

    1/16/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

    – Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT – WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today reported a corporate update and anticipated 2026 pivotal milesto

    1/7/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lurker Nancy converted options into 75,133 shares, increasing direct ownership by 34% to 294,346 units (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    1/7/26 4:13:32 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Duker Jay S. converted options into 20,793 shares and covered exercise/tax liability with 10,054 shares, increasing direct ownership by 16% to 77,752 units (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    1/7/26 4:12:52 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Elston George converted options into 15,285 shares and covered exercise/tax liability with 4,487 shares, increasing direct ownership by 13% to 91,852 units (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    1/7/26 4:12:02 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    SEC Filings

    View All

    EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EyePoint, Inc. (0001314102) (Filer)

    1/7/26 7:05:26 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by EyePoint Pharmaceuticals Inc.

    8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)

    12/8/25 9:49:43 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by EyePoint Pharmaceuticals Inc.

    144 - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    12/4/25 10:24:55 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zaderej Karen L. bought $59,000 worth of shares (10,000 units at $5.90), increasing direct ownership by 38% to 36,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/19/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Zaderej Karen L. bought $54,450 worth of shares (10,000 units at $5.45), increasing direct ownership by 61% to 26,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/15/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dicicco Wendy F bought $19,997 worth of shares (2,567 units at $7.79), increasing direct ownership by 35% to 9,967 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    8/21/24 4:32:51 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

    Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    1/7/25 7:52:05 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on EyePoint Pharmaceuticals

    Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform

    10/16/24 8:38:45 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 3:10:08 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 1:22:34 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/12/24 2:31:58 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Financials

    Live finance-specific insights

    View All

    EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

    WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/fgkir3sg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharm

    10/29/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

    – Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuti

    8/6/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

    WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the

    7/30/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Leadership Updates

    Live Leadership Updates

    View All

    EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

    WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San

    1/8/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

    WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future

    9/4/24 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

    - Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists

    4/2/24 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials